Focuses on developing antibody-based therapies for the treatment of severe autoimmune diseases and cancer.
argenx SE is a prominent biotechnology company dedicated to advancing therapies for autoimmune diseases across global markets, including the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. Established in 2008 and headquartered in Breda, the Netherlands, the company is at the forefront of developing innovative treatments aimed at addressing significant unmet medical needs. argenx's flagship product candidate, efgartigimod, is currently undergoing Phase III clinical trials for multiple conditions such as myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy.
In addition to efgartigimod, argenx is advancing a robust pipeline of immunology innovation programs. These include cusatuzumab, targeting hematological cancers and high-risk myelodysplastic syndromes (MDS), as well as ARGX-119, an antibody designed to address muscle-specific tyrosine kinase in various stages. The company also focuses on ARGX-117 for severe autoimmune indications, ARGX-118 for airway inflammation, and ARGX-120 for treating autoimmune diseases. Furthermore, argenx collaborates extensively through strategic partnerships with industry leaders such as AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, and maintains numerous collaboration and license agreements with institutions and organizations globally.
With a commitment to scientific excellence and therapeutic innovation, argenx SE continues to expand its portfolio of partnered product candidates, including ARGX-115 for cancer treatment, ARGX-112 targeting the interleukin-22 receptor, and ARGX-114 directed against the MET receptor. Through these collaborations, argenx aims to accelerate the development of novel therapies that significantly improve outcomes for patients battling autoimmune diseases and hematological cancers worldwide.